STOCKHOLM, August 19, 2026 /PRNewswire/ — BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and Mesenkia Therapeutics announced today that the companies have signed a research collaboration agreement to explore a novel antibody-based approach for glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer, where effective delivery of large molecules to the brain remains a major challenge.

The collaboration combines BioArctic’s proprietary BrainTransporter™ technology with an antibody, developed with Mesenkia’s KITAIbodies® platform. The antibody targets HVEM[1], a protein found on the surface of certain glioblastoma tumor cells, including tumor stem cells. By addressing these cells, which are thought to contribute to tumor recurrence and treatment resistance, the project aims to unlock new treatment possibilities for patients with a very high unmet medical need.

Under the agreement, BioArctic will be responsible for generating a novel drug candidate by combining its BrainTransporter technology with Mesenkia’s antibody. BioArctic and Mesenkia thereafter plan to perform preclinical studies to validate the concept and, based on the results of these studies, decide on next steps.

This research collaboration represents an important step in expanding BioArctic’s BrainTransporter pipeline into oncology and further validates the platform’s potential beyond neurodegenerative diseases. It also builds on BioArctic’s core expertise in development and delivery of pharmaceuticals to the brain.

“We are excited to broaden our research and take a first step into oncology through this collaboration,” said Gunilla Osswald, Chief Executive Officer of BioArctic. “Glioblastoma remains one of the most challenging cancers to treat, with limited therapeutic options and poor prognosis for those affected. By combining our BrainTransporter technology with Mesenkia’s innovative antibody approach, we aim to target key disease-driving mechanisms to develop new ways to treat this devastating disease.”

“This agreement marks an important step for Mesenkia and creates clear opportunities to explore a new treatment strategy for patients with glioblastoma together with BioArctic. The need for new treatments is substantial, particularly given the challenge of delivering medicines to tumor cells throughout the brain. By combining Mesenkia’s antibody expertise with BioArctic’s BrainTransporter technology, we can address one of the disease’s key barriers in a new way. We look forward to advancing the concept together with BioArctic, with the long-term goal of enabling better treatment options for patients and their loved ones,” said Moa Fransson, Chief Executive Officer of Mesenkia.

The information was released for public disclosure, through the agency of the contact person below, on August 19, 2026, at 11:15 am CET.

For further information, please contact: 
BioArctic
Oskar Bosson, Chief Investor Relations & Communications Officer
E-mail: oskar.bosson@bioarctic.com
Telephone: +46 704 107 180

Jenny Ljunggren, External Communications and Investor Relations Manager
E-mail: jenny.ljunggren@bioarctic.com
Telephone: +46 76 013 86 08

Mesenkia
Moa Fransson, CEO
E-mail: moa.fransson@mesenkia.com
Telephone: +46 072 211 71 61

About Mesenkia Therapeutics AB

Mesenkia is a pre-clinical company developing the next-generation biological drug candidates designed to treat the aggressive brain tumor glioblastoma. Mesenkia is founded on world leading science from Uppsala University and the University of Tokyo originating from decades of collaborations dedicated to finding the root cause for tumor pathogenesis. The company’s lead program targets glioblastoma, while their KITAIbodies® are designed to enable future therapeutics across multiple indications and modalities. Through strategic collaborations with pharmaceutical companies, Mesenkia aims to accelerate drug development and create value for patients worldwide.

About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world’s first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer’s disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson’s disease and ALS as well as additional projects against Alzheimer’s disease. Several of the projects utilize the company’s proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic’s B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

[1] Herpes virus entry mediator, a protein that is part of the tumor necrosis factor (TNF) receptor superfamily.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioarctic/r/bioarctic-and-mesenkia-enter-oncology-research-collaboration,c4385181

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/bioarctic-and-mesenkia-enter-oncology-research-collaboration-302855134.html

Approximately 60 Financial Advisors Representing $7.2 Billion in Client Assets Gather in New York City

Annual Program Reflects Oppenheimer’s Continued Investment in the Development and Long-Term Success of Its Next Generation of Advisors

NEW YORK, Aug. 19, 2026 /PRNewswire/ — Oppenheimer & Co. Inc. (Oppenheimer), a leading investment bank, wealth manager and subsidiary of Oppenheimer Holdings Inc. (NYSE: OPY), recently hosted its fifth annual Next-Gen Peer-to-Peer Forum in New York City, bringing together approximately 60 Financial Advisors from across the country.

Held at One World Trade Center overlooking Lower Manhattan, the program gave attendees an opportunity to exchange ideas, discuss common challenges and learn from one another. Collectively, the participating advisors represent approximately $7.2 billion in assets under management and $41 million in annual revenue.

“Now in its fifth year, the Next-Gen Peer-to-Peer Forum reflects Oppenheimer’s commitment to investing the time and resources into developing the next generation of advisors,” said Ed Harrington, Executive Vice President and Head of Oppenheimer’s Private Client Division. “The event brings together advisors who are building substantial businesses but at the same time navigating similar challenges. By giving them a setting to speak candidly and share practical insights, we help them strengthen how they serve clients and continue growing their practices.”

Oppenheimer developed the Next-Gen Peer-to-Peer Forum to help emerging leaders develop the skills, relationships and perspective required to build successful careers. The program forms part of the firm’s broader investment in the long-term success of its advisor workforce.

Discussions throughout the program focused on the issues shaping the future of the wealth management industry and the decisions that will influence the growth of attendees’ businesses. Topics included building scalable practices, developing effective teams, incorporating artificial intelligence and other technologies to improve efficiency, differentiating investment advice and positioning practices to meet the evolving expectations of future generations of clients.

The Forum also encouraged attendees to challenge conventional thinking and offer candid perspectives on what it takes to compete in a rapidly changing industry. Their engagement, thoughtfulness and willingness to contribute underscored the strength of Oppenheimer’s next generation of advisors.

“The Peer-to-Peer Forum works because the advisors drive the conversation,” said Nicholas Siconolfi, Managing Director and Head of National Sales for Oppenheimer’s Private Client Division. “Each of our Next Gen advisors brings a unique perspective, but they all share a common goal of continuously enhancing the client experience while building practices designed to endure and adapt. The ideas exchanged throughout the forum help shape the future of our firm. Our advisors learn from one another, and as leaders, we gain invaluable firsthand insight into what they need to succeed. Every year, this event reinforces that the future of our firm is in very capable hands.”

“Oppenheimer is an ideal place for advisors to build and grow their careers over time,” Harrington added. “We are committed to giving talented advisors the tools, resources and support they need to succeed, and the Next-Gen Peer-to-Peer Forum is an important part of that commitment. It helps emerging leaders strengthen their professional networks, develop as business owners and play a meaningful role in the future of the firm. We believe the most important investment we can make is in our people. The firms that endure are those that develop talent, not simply acquire it. By bringing together advisors who are committed to building exceptional practices, we are helping to develop the next generation of leaders while strengthening the long-term future of Oppenheimer and the clients we serve.”

About Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc., a major subsidiary of Oppenheimer Holdings Inc. (NYSE: OPY), is a leading middle-market investment bank and full-service broker-dealer. The firm provides a broad range of investment banking, securities brokerage and wealth management services to corporations, institutions and high-net-worth individuals.

Media Contact:
Mitch Manning
Haven Tower Group LLC
424 317 4858
mmanning@haventower.com

View original content:https://www.prnewswire.com/news-releases/oppenheimer-hosts-fifth-annual-next-gen-peer-to-peer-forum-302854634.html

SOURCE Oppenheimer & Co. Inc.

Company recognized for modernizing student mobility through its AI-powered Zum CMX platform

REDWOOD CITY, Calif., Aug. 19, 2026 /PRNewswire/ — Zūm, a leader in modern student mobility, today announced that it has been selected as a finalist in three categories by the 2026 Reuters Global Sustainability Awards.

The prestigious awards recognize companies that show “unwavering dedication to pioneering sustainable business models and advancing the transition towards a net-zero future.” Zum is a finalist for the Product Innovation Award, the Small-Medium Enterprise of the Year Award, and the SDG Pioneer Award. This is the second year in a row that Zum has been recognized as a finalist.

“Zum is proud to be advancing a new era of safe, modern student mobility that sets kids up for success in the classroom and delivers lasting benefits to entire communities,” said Ritu Narayan, Founder and CEO of Zum. “Zum’s Connected Mobility Experience (CMX) — a unified, AI-powered operating system purpose-built for student mobility — is delivering measurable results and expanding access to education nationwide. It is an honor to be recognized as a finalist in the 2026 Reuters Global Sustainability Awards.”

Zum is transforming the $40 billion student mobility market through Zum CMX, which connects routing, dispatch, drivers, schools, families, safety, vehicles, and operations in real time. Zum CMX helps districts improve reliability, efficiency, transparency, and the overall student experience.

Additionally, Zum views electrification as the next step in a broader modernization journey that combines technology, operations, transportation infrastructure, and energy infrastructure. Zum employs its vehicle-to-grid (V2G) technology and bidirectional charging to return energy from electric school buses to the grid. In 2024, Zum launched the U.S.’s first fully electrified school bus fleet in Oakland, CA, with V2G technology. This year, it announced an all-electric school bus fleet in San Francisco Unified — making this bidirectional EV fleet the largest in the country — and the first and largest fully electric, bidirectional fleet in the Northeast for Branford Public Schools (CT).

Today, Zum serves more than 6,500 schools across 18 states nationwide. Zum delivers an average 98% on-time performance and has earned 4.9 out of 5 stars across more than 1.7 million parent ratings.

Winners of the 2026 Reuters Global Sustainability Awards will be announced Oct. 21 in London. Learn more and see the list of finalists here.

To learn more about how Zum is leading the nation in safe and reliable student mobility, visit www.ridezum.com.

About Zum

Zum is modernizing mass mobility with its Connected Mobility Experience (CMX) that connects and coordinates people, vehicles, and operations in real time. In the student mobility market, Zum is addressing a daily source of anxiety and disruption by providing a reliable, transparent, and efficient mobility experience for students and families. Learn more at www.ridezum.com. Today, more than 6,500 schools in 18 states have relied on the Zum CMXTM system.

Media Contact

Jenny Mayfield
VP, Communications, Zum
press@ridezum.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/zum-named-as-a-finalist-in-the-2026-reuters-global-sustainability-awards-302854612.html

SOURCE Zūm